Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review.

IF 4.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY Clinical Pharmacokinetics Pub Date : 2024-05-01 Epub Date: 2024-05-04 DOI:10.1007/s40262-024-01373-4
Keng Wah Foong, Sook Hui Chaw, Yoke Lin Lo, Pui San Loh
{"title":"Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review.","authors":"Keng Wah Foong, Sook Hui Chaw, Yoke Lin Lo, Pui San Loh","doi":"10.1007/s40262-024-01373-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The establishment of optimal dosing regimens for intravenous (IV) lidocaine in the perioperative setting, aiming to balance effective pain relief with minimisation of potential side effects, is a topic of ongoing debate. This discussion stems from the significant variability in lidocaine's pharmacokinetic (PK) parameters and its relatively narrow safety margin. Population pharmacokinetic (popPK) modelling has emerged as a valuable tool for understanding the factors contributing to this observed variability in drug kinetics.</p><p><strong>Objectives: </strong>This systematic review compiles the existing knowledge on lidocaine's PK properties and published popPK models, with a focus on significant covariates.</p><p><strong>Methods: </strong>A systematic search on Cochrane CENTRAL, Medline, and EMBASE was performed from inception to June 2023. Original clinical studies that administered IV lidocaine to adults and performed PK analyses using a nonlinear mixed effects modelling approach were included. The quality of the included studies was assessed by compliance with the Clinical Pharmacokinetics (ClinPK) statement checklist.</p><p><strong>Results: </strong>Seven studies were included, which involved a diverse adult population, including both volunteers and patients with various comorbidities. Lidocaine PK was primarily characterised by a two- or three-compartment model. The volume of distribution at steady state ranged from 66 to 194 L, and the total clearance ranged from 22 to 49 L/h. Despite adjusting for significant covariates like heart failure status, alpha-1-acid glycoprotein, duration of lidocaine infusion, and body weight, each study revealed substantial variability in PK parameters. The potential impact of hepatic or renal function biomarkers on these PK parameters calls for further investigation. Incomplete reporting of key aspects of developed models may hinder the models' reliability and clinical application.</p><p><strong>Conclusion: </strong>The findings emphasise the importance of tailoring drug dosage to ensure the safe and effective use of intravenous lidocaine. Optimal design methodologies may be incorporated for a more efficient identification of important covariates. Utilising contemporary model evaluation methods like visual predictive checks and bootstrapping would enhance the robustness of popPK models and the reliability of their predictions. This comprehensive review advances our understanding of lidocaine's pharmacokinetics and lays the groundwork for further research in this critical area of perioperative pain management. Review protocol registered on 25 August 2023 in PROSPERO (CRD42023441113). This work was supported by the Fundamental Research Grant Scheme, the Ministry of Higher Education, Malaysia (FRGS/1/2020/SKK01/UM/02/2).</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":" ","pages":"623-643"},"PeriodicalIF":4.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-024-01373-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The establishment of optimal dosing regimens for intravenous (IV) lidocaine in the perioperative setting, aiming to balance effective pain relief with minimisation of potential side effects, is a topic of ongoing debate. This discussion stems from the significant variability in lidocaine's pharmacokinetic (PK) parameters and its relatively narrow safety margin. Population pharmacokinetic (popPK) modelling has emerged as a valuable tool for understanding the factors contributing to this observed variability in drug kinetics.

Objectives: This systematic review compiles the existing knowledge on lidocaine's PK properties and published popPK models, with a focus on significant covariates.

Methods: A systematic search on Cochrane CENTRAL, Medline, and EMBASE was performed from inception to June 2023. Original clinical studies that administered IV lidocaine to adults and performed PK analyses using a nonlinear mixed effects modelling approach were included. The quality of the included studies was assessed by compliance with the Clinical Pharmacokinetics (ClinPK) statement checklist.

Results: Seven studies were included, which involved a diverse adult population, including both volunteers and patients with various comorbidities. Lidocaine PK was primarily characterised by a two- or three-compartment model. The volume of distribution at steady state ranged from 66 to 194 L, and the total clearance ranged from 22 to 49 L/h. Despite adjusting for significant covariates like heart failure status, alpha-1-acid glycoprotein, duration of lidocaine infusion, and body weight, each study revealed substantial variability in PK parameters. The potential impact of hepatic or renal function biomarkers on these PK parameters calls for further investigation. Incomplete reporting of key aspects of developed models may hinder the models' reliability and clinical application.

Conclusion: The findings emphasise the importance of tailoring drug dosage to ensure the safe and effective use of intravenous lidocaine. Optimal design methodologies may be incorporated for a more efficient identification of important covariates. Utilising contemporary model evaluation methods like visual predictive checks and bootstrapping would enhance the robustness of popPK models and the reliability of their predictions. This comprehensive review advances our understanding of lidocaine's pharmacokinetics and lays the groundwork for further research in this critical area of perioperative pain management. Review protocol registered on 25 August 2023 in PROSPERO (CRD42023441113). This work was supported by the Fundamental Research Grant Scheme, the Ministry of Higher Education, Malaysia (FRGS/1/2020/SKK01/UM/02/2).

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人静脉注射利多卡因的群体药代动力学:系统回顾
背景:在围手术期静脉注射利多卡因(IV)的最佳剂量方案的确定,旨在兼顾有效止痛和最大限度地减少潜在副作用,是一个一直争论不休的话题。这一讨论源于利多卡因药代动力学(PK)参数的显著可变性及其相对较窄的安全范围。群体药代动力学(popPK)建模已成为了解导致药物动力学变异因素的重要工具:本系统综述汇编了有关利多卡因 PK 特性的现有知识和已发表的 popPK 模型,重点关注重要的协变量:方法:从开始到 2023 年 6 月,在 Cochrane CENTRAL、Medline 和 EMBASE 上进行了系统检索。纳入了为成人静脉注射利多卡因并使用非线性混合效应建模方法进行 PK 分析的原始临床研究。纳入研究的质量按照临床药代动力学(ClinPK)声明核对表进行评估:结果:共纳入了七项研究,涉及不同的成人群体,包括志愿者和患有各种合并症的患者。利多卡因的 PK 主要以二室或三室模型为特征。稳态分布容积从 66 升到 194 升不等,总清除率从 22 升到 49 升/小时不等。尽管对心力衰竭状态、α-1-酸性糖蛋白、利多卡因输注持续时间和体重等重要协变量进行了调整,但每项研究都显示 PK 参数存在很大差异。肝功能或肾功能生物标志物对这些 PK 参数的潜在影响需要进一步研究。对已开发模型的关键方面报告不全可能会妨碍模型的可靠性和临床应用:研究结果强调了调整药物剂量以确保安全有效使用静脉注射利多卡因的重要性。为了更有效地识别重要的协变量,可采用优化设计方法。利用视觉预测检查和自引导等现代模型评估方法将提高 popPK 模型的稳健性及其预测的可靠性。这篇综合性综述加深了我们对利多卡因药代动力学的理解,为围手术期疼痛治疗这一关键领域的进一步研究奠定了基础。综述方案于 2023 年 8 月 25 日在 PROSPERO 注册(CRD42023441113)。这项工作得到了马来西亚高等教育部基础研究资助计划(FRGS/1/2020/SKK01/UM/02/2)的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.80
自引率
4.40%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
期刊最新文献
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study. Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding. Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis. SGLT2 Inhibitors in Patients with Heart Failure: A Model-Based Meta-Analysis. Population Pharmacokinetics of Intravenous Paracetamol and Its Metabolites in Extreme Preterm Neonates in the Context of Patent Ductus Arteriosus Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1